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1. BACKGROUND AND RATIONALE 
Cervical screening (the ‘smear test’) helps prevent cervical cancer by finding early signs of 
abnormalities that can be addressed before they progress to cancer. Another way to prevent 
disease is to block infection by the human papillomavirus (HPV) types that can lead, usually 
after many years, to the development of cervical cancer. There are two vaccines now 
approved for use in many countries worldwide, including the UK: CervarixTM (GlaxoSmithKline; 
GSK) and GardasilTM (Merck).  
 
The UK introduced HPV immunisation for girls in September 2008 using the HPV vaccine 
CervarixTM. The routine programme will target 12-13 year old girls and there will be a catch-up 
programme for girls up to 18 years. The first cohort to be immunised are girls born between 1st 
September 1995 and 31st August 1996 (current school year 8). Immunisation consists of a 
three-dose schedule over a six month period, starting in Autumn 2008.  A schools-based 
programme has been recommended. The catch-up programme will target all girls born 
between 1st September 1990 and 31st August 1991 (current school year 13) alongside the 
first routine cohort (starting in Autumn 2008). The remaining catch-up years will be offered 
HPV vaccine from September 2009. The Joint Committee for Vaccination and Immunisation 
(JCVI) advised that a catch-up campaign for all women aged 18 years and over was not cost 
effective, but that HPV immunisation may be of benefit to individual women and further advice 
regarding this is anticipated from the Department of Health. 
 
There are many types of HPV virus, some of which are cancer-causing (oncogenic). Both the 
vaccines (CervarixTM or GardasilTM) should protect women against two of the most common 
oncogenic HPV types, 16 and 18, which account for about 70% of cervical cancer. However, 
as there are many other HPV types that also cause cervical cancer it will be necessary to 
maintain the cervical cancer screening programme. This is a significant recurrent investment 
by the NHS to protect the UK population from this devastating disease.  
 
In this study, we will examine the immune responses to immunisation with each vaccine and 
assess how effective these vaccines may be against other oncogenic types of HPV; this is 
known as cross-protection. We will also determine if differences in vaccine components and/or 
their formulation impact on this level of cross-protection. This information will be used to help 
predict what will happen to each HPV type when the population is vaccinated and so predict 
gaps in protection that can be filled by the next generation of vaccines. This information may 
also help to target limited NHS resources to those individuals who may not be sufficiently 
protected by vaccination. 
 
1.1 Vaccine Characteristics and Immunization Schedules 
 
CervarixTM and GardasilTM vaccines contain virus-like particles (VLP) based on the oncogenic 
HPV types 16 and 18. VLPs are non-infectious and comprise self-assembled L1 (major 
capsid) proteins. They do not contain the virus genome and so only physically resemble virus 
particles. GardasilTM also includes VLPs based on the non-oncogenic HPV types 6 and 11, 
which are associated with genital warts. There are other differences between the vaccines, 
summarized in Table 1.1: 
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Table 1.1 Vaccine characteristics 
 
 
Characteristic 
  
CervarixTM 
 
 
GardasilTM 
    
Manufacturer  GSK Merck / Sanofi Pasteur MSD 
    
VLP  16/18 6/11/16/18 
    
Production source   Insect cells, Trichnoplusia ni Yeast cells, Saccharomyces cerevisiae 
    
Dose  20/20 µg per dose 20/40/40/20 µg per dose 
    
Adjuvant  Proprietary ASO4 comprised of 
500 µg of aluminum hydroxide 
and 50 µg of 3-deacylated 
monophosphoryl lipid A (MPL) 
225 µg Aluminum (as amorphous 
aluminum hydroxyphosphate sulphate) 
    
Immunization  0.5mL IM 0.5mL IM 
    
Recommended schedule  0, 1, 6 months 0, 2, 6 months 
    
Schedule flexibility  None stated Three doses in 12 month period, 
minimum 1 month between dose 1 & 2, 
minimum 3 months between dose 2 & 3 
    
 
1.2 Available data 
 
Following many small-scale trials examining proof-of-principle issues, several large, 
multicentre and in many cases, international-scale Phase III vaccine trials have been 
conducted in young women showing almost complete protection from infection with HPV types 
16 or 18 and subsequent occurrence of pre-cancerous (Cervical Intraepithelial Neoplasia, 
CIN2+) lesions. A few recently published examples are highlighted below. 
 
FUTURE I and FUTURE II were 3 year randomized, double-blind, placebo-controlled studies 
using the GardasilTM vaccine. FUTURE I included 5455 healthy women aged 16-24 years old 
and demonstrated 100% (95% CI = 94-100) protection against cervical lesions associated with 
vaccine types HPV 16 and 18 (Garland et al., 2007). FUTURE II, included 12,167 health 
women 15-26 years old and demonstrated 98% (95% CI = 86-100) protection against cervical 
lesions associated with vaccine types HPV 16 and 18 (FUTURE II Study Group 2007). 
 
The PATRICIA study, a 2 year, randomized, double-blind study using CervarixTM and Hepatitis 
A as a control arm was conducted in 18,644 healthy women aged 15-25 years old. This study 
included participants from Europe, North America, Latin and South America and the Asian-
Pacific region. Vaccine-induced protection against high grade CIN2+ lesions associated with 
the vaccine types 16 and 18 was 90% (95% CI = 53-99) (Paavonen et al., 2007).  
 
As the majority (>95%) of cervical cancers are associated with HPV types belonging to just 
two distinct Alpha-papillomavirus clades, A9 (16, 31, 33, 35, 52 and 58) and A7 (18, 39, 45, 59 
and 68), the extent to which immune responses induced by vaccination with HPV types 16 and 
18 will cross-protect with related HPV types is a critical question in the field today. Emerging 
trial data suggests that some degree of cross-protection is induced by the current HPV 
vaccines, in particular against HPV types 45 and 31. In the PATRICIA (CervarixTM) study, for 
example, potential cross-protection against HPV 31 (36·1% [95% CI = 0·5-59·5; p=0·0173]), 
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HPV 45 (59·9% [95% CI = 2·6-85·2; p=0·0165]) and HPV 52 (32% [95% CI = 3·5-51·9; 
p=0·0093]) associated cervical lesions. Preliminary data from a GardasilTM efficacy study 
demonstrated vaccine efficacy against CIN1-3 or AIS associated with HPV 31 or 45 of 62% 
(95% CI = 10-85) and associated with HPV 31, 33, 45, 52, or 58 of 43% (95% CI = 7-66) 
(Brown et al., 2007). A comparison study of CervarixTM versus GardasilTM in women between 
18 and 45 years of age has recently been initiated and, as of Oct 9th 2008 had completed 
recruitment, but no data are yet available (NCT00423046: http://clinicaltrials.gov).  
 
This supports the scientific evidence that immunisation of mice with HPV VLPs can induce a 
limited cross-reactive response against related HPV genotypes; for example HPV 16 VLP 
induces antibodies against HPV 16 and 31 while immunisation of mice or humans with HPV 18 
VLP often induces antibodies against HPV 45 (Giroglou et al., 2001; Combita et al., 2002; 
Smith et al., 2007).  
 
The mechanism by which these antibodies protect against HPV infection or incident disease is 
not entirely clear, but is likely to involve antibodies acting to protect the barrier surface of the 
cervical mucosa. These antibodies could be mucosally-secreted antibodies or peripheral 
antibodies acting at the cervical site following microtrauma, the predicted mode of infection for 
HPV. A recent study looked at mucosal antibodies and found a good correlation between HPV 
antibody levels in the blood and mucosa secretions, although the specificities of these 
antibodies were not fully described highlighting further need for study in this area (Kemp et al., 
2008). The role of HPV-specific T cells in the co-ordination of the immune response against 
HPV has been examined in some detail over recent years and there is emerging evidence for 
the generation of limited cross-reactive T cell responses induced by HPV vaccination (e.g. 
Pinto et al., 2006).  
 
Although the full extent of cross-protection will only become clear over time as incident 
infections accumulate in both the vaccine and control arms of these multinational vaccine 
studies, it is certain that the current generation of vaccines will not be adequately protective 
against all oncogenic HPV types. Thus, an assessment of the limitations of the current 
generation of HPV vaccines and data helping to inform the formulation of the next generation 
of HPV vaccines is particularly needed.  
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2. OBJECTIVES      
 
To undertake a comprehensive comparative evaluation of the HPV-specific immune responses 
against oncogenic HPV types induced when adolescent female subjects are vaccinated with 
either CervarixTM or GardasilTM, by  
 
(i) examining the levels of antibody-mediated cross-neutralisation elicited to oncogenic 
HPV types following vaccination with either CervarixTM or GardasilTM 
 
(ii) comparing the levels and patterns of cross-neutralisation induced by each vaccine 
to highlight potential differences in immunogenicity between the vaccines 
 
(iii) assessing whether there are differences in the specificity of mucosal antibodies or 
cell-mediated immune responses elicited by each vaccine 
 
3. STUDY DESIGN           
 
This will be a phase IV randomised study comparing the immune responses elicited in young 
girls (<18 years old) receiving the HPV vaccine GardasilTM or CervarixTM. Subjects will receive 
three vaccinations and have four sets of samples collected according to the table below. 
 
To facilitate a comparison of immune responses elicited to the two vaccines, the schedules 
have been synchronized wherein each individual will be vaccinated at months 0, 1 and 6. 
Schedule flexibility has been highlighted for GardasilTM: Subjects evaluated in the Per Protocol 
population received all 3 vaccinations within 1 year of enrolment. An analysis of immune 
response data suggests that flexibility of ±1 month for Dose 2 (i.e., Month 1 to Month 3 in the 
vaccination regimen) and flexibility of ±2 months for Dose 3 (i.e., Month 4 to Month 8 in the 
vaccination regimen) do not impact the immune responses to GardasilTM 
(www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf; Merck & Co., Inc. 
September 2008: #9883608). Calculation of subsequent appointments will be based on the 
last appointment date rather than time zero.  
 
 Timepoint (months) 
 
GROUP 
 
0 
1 
(-2 days/ 
+2 weeks) 
2 
(± 1 week) 
6 
(± 1 week) 
7 
(± 1 week) 
12 
(± 1 week) 
 
 
1 
(n=200) 
CervarixTM 
 
Blood 
sample 
 
CervarixTM 
 
 
 
 
Blood 
sample 
 
CervarixTM 
 
 
 
 
Samples (incl. 
extra blood 
and optional 
sponge) 
 
 
 
 
Blood 
sample 
 
 
2 
(n=200) 
 
GardasilTM 
 
Blood 
sample 
 
 
GardasilTM 
 
 
 
 
Blood 
sample 
 
GardasilTM 
 
 
 
Samples (incl. 
extra blood 
and optional 
sponge) 
 
 
 
 
Blood 
sample 
Activity Month 
Vaccination (CervarixTM or GardasilTM) 0 1 2 3 4 5 6 7 8 9 10 11 12 
Blood taken by Vaccine Research Nurses 0 1 2 3 4 5 6 7 8 9 10 11 12 
Voluntary self-taken lower vaginal sponge 0 1 2 3 4 5 6 7 8 9 10 11 12 
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“Samples” denotes the collection of: 
 
• 5mL blood (clotted) at Month 0, 2, 7 and 12 
• 20-30mL blood (heparinised) at Month 7 may also be taken 
• (Optional) self-collected lower vaginal sponge on Month 7 
 
SUBJECT ELIGIBILITY         
 
Inclusion criteria: 
• Aged between 12 and 15 years at the time of the first immunisation 
• Female 
• No contraindications to vaccination as specified in the “Green Book” – Immunisation 
Against Infectious Disease, HMSO. 
• Written informed consent obtained from parent or guardian of subject 
 
Exclusion criteria 
• Pregnant or become pregnant during the course of the trial (no contraindications to 
vaccination for those taking the contraceptive pill).  
• Breast-feeding mothers 
• Allergic to vaccine components 
 
Deferral 
• Subjects who have a fever (axillary temperature ≥ 38°C), or have an acute infection will 
have injection delayed until resolution 
• Not recommended in patients undergoing immunosuppressive therapy 
• Not recommended for persons already undergoing vaccination as effect of co-
immunisation with other vaccines has not been rigorously tested 
• The JCVI (17 Oct 2007, 18 Jul 2008) advises that HPV vaccines and the Td/IPV school 
leaver booster (low dose diphtheria, tetanus and inactivated polio: Td/IVP) can be co-
administered 
 
Withdrawal criteria 
• Subject becomes pregnant 
• Subject or parent/guardian withdraws consent or lost to follow-up (HPA’s SOP on 
Premature Withdrawal from a Study will be followed). 
 
Girls aged 12 to 15 years will be recruited to this study. It is assumed that the immune 
response of these girls will not differ from that of girls vaccinated age 12-13 years as part of 
the routine HPV vaccination. 
 
NUMBER OF SUBJECTS AND DURATION OF STUDY      
 
A total of four hundred (400) subjects will be recruited through two centres: North Hertfordshire 
and Gloucester. 
 
It is hoped that recruitment to the study will be completed in a 10-month timeframe. However, 
as with all adolescent studies, the recruitment rate depends on patient attitude and is largely 
unpredictable. Experience with previous studies in this age group with the number of Vaccine 
Research Nurses (VRNs) who will recruit to this study gives a recruitment estimate of 10-15 
adolescents per week.  
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CONDUCT OF THE STUDY      
 
A. Recruitment      
 
Recruitment will be conducted through schools and general practitioners. 
 
General practitioners will be approached to agree to the participation of their surgery in the 
study and will be asked to document their agreement to the study being conducted in their 
surgery by the completion of a protocol approval form (Appendix 6). No subjects will be 
recruited from a surgery until this has been obtained. A site file will be provided to each 
participating surgery, with documents as listed in the index (Appendix 4). Study investigators 
and co-ordinators will be available to contact should health professionals or parents require 
any further information.   
 
Subjects will be recruited from general practices in Hertfordshire and Gloucestershire. 
Recruitment and follow up will be by dedicated Vaccine Research Nurses (VRNs) currently 
employed by the Health Protection Agency. 
 
For school-based recruitment, school staff will identify potential participants based solely on 
age and gender and give/send the initial invitation to participate both to the girl and a 
parent/guardian. Only girls returning forms requesting further information about the study will 
be contacted by the Vaccine Research Nurses and contact numbers will be provided for 
parents and students who require further information about the study. As well as the approved 
study information leaflet families will be provided with the standard Department of Health 
information about HPV vaccination and will have the opportunity to discuss the study with 
dedicated Vaccine Research Nurses and / or medical staff should they wish to do so. 
Information will be provided in a timely manner to ensure parents/participants have time to 
seek the opinion of others, should they wish, such as family, friends and other health 
professionals. Schools will decide the most appropriate methods for identifying potential 
participants from their registered pupils. It is anticipated that this will almost invariably be via a 
computerised search of registered female pupils of eligible age.  
 
Written information will be provided about the study and clinicians will discuss the study with 
individuals and answer any questions before obtaining written informed consent for 
participation for those who wish to enrol. Because subjects will be under 16 years of age, the 
patient information leaflet will encourage informed discussion of the study with a parent or 
guardian. 
 
Following confirmation of inclusion and exclusion criteria, subjects will be enrolled in the study 
and will be allocated to one of the two treatment groups by a randomisation procedure – see 
below. No study procedure will be undertaken until written informed consent is given by a 
parent or guardian and the inclusion/exclusion criteria are verified.  
 
GPs will be informed of the participation of each subject in the study by a letter (please see 
Appendix 1). Provision of this information forms part of the consent procedure.  
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B. Presentation and Labelling of Study Vaccines   
The vaccines to be used in this study are licensed for use in the UK. The study will be 
registered for Clinical Trial Authorisation (CTA) by the HPA.  
 
Supplies of the vaccines: CervarixTM and GardasilTM will be reserved by the CfI from the 
Department of Health for use in this study. Vaccines will be labelled for the study at HPA CfI 
according to the appropriate Standard Operating Procedure. The full information required by 
annex 13 of the GMP rules and guidance is listed below (a-k):   
a. name of the sponsor 
b. pharmaceutical dosage form, route of administration, quantity of dosage units  
c. the batch/code number to identify contents 
d. trial subject identification number where applicable 
e. directions for use 
f. ‘for clinical trial use only’ 
g. the name of the investigator (if not already included as part of a code) 
h. a trial reference code allowing identification of the trial and investigator 
i. the storage conditions 
j. the period of use (use-by date/ expiry date or retest date) in month/year 
k. ‘keep out of reach of children’ except when the product is for use only in hospital 
 
On receipt of the vaccine each dose will have information pertaining to batch, storage 
conditions, directions for use, expiry date and dosage already printed. HPA will add the label 
below to the prefilled syringe in order to comply with the full information required by annex 13 
of GMP.  The HPA’s label will contain a statement that the vaccine is for trial-use only, name of 
Chief Investigator and protocol code. Sample label:  
 
For HPA Clinical Trial Use Only 
CI: Prof E Miller  
Protocol: HPV CSP01 
 
The additional trial labels will be placed in a position so as not to obscure information such as 
batch number and expiry date as on the label the vaccine is supplied with. A label containing 
the same information will be attached to the box containing the vaccine.  In addition, if any of 
the information listed in a-k above is not already printed on the box, a label containing this 
information will also be attached to the box, taking care not to obscure any information already 
there. 
 
Vaccine reconciliation or dose accountability will be conducted for all study designated vaccine 
doses according to standard operating procedures in place at the CfI. The batch numbers for 
all vaccinations will be recorded by Vaccine Research Nurses (VRNs) on administration. 
 
C. Dispatch of Vaccines to Clinics     
The vaccines will be dispatched to the GP clinics or designated vaccine storage area from CfI 
or Gloucester HPA in appropriate packaging with temperature control and monitoring which 
will indicate whether the vaccine has been stored at temperatures outside the recommended 
range. The vaccines will be stored in a secure temperature-controlled environment according 
to usual practice. If vaccines are damaged or have been exposed to temperatures outside the 
permitted range, replacement doses will be used. 
 
All vials used will be returned to CfI with Case Report Forms (CRFs) for storage. Any vials that 
have been wasted or have expired by the end of the study will be disposed of according to 
local practice, or will be returned to CfI for disposal. Accountability forms will be completed. 
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D. Vaccination Procedure 
The Vaccine Research Nurses (VRNs) will administer vaccinations at designated GP surgeries 
or schools. Before each dose is given, the VRN will take the subject’s temperature. 
Vaccination will be deferred if the temperature measured is >38oC, or if there is acute illness 
on the day of vaccination.  
 
The VRN will administer vaccines by intramuscular injection in the non-dominant arm. Before 
each dose is given the VRN will record that the vaccine has been maintained under 
appropriate storage conditions. The VRN will write the subject’s initials and date onto an 
adhesive label bearing the subject number and stick this onto the empty vaccine containers, 
which will be returned with the CRFs to CfI.  
 
Standard immunisation practices and appropriate precautions for any anaphylactic reaction 
will be followed. The HPA’s SOP on Reporting Serious Adverse Events (SOP28) will be 
followed for classifying events and reporting SUSARs to the appropriate authorities and 
manufacturers. 
 
Participants’ GPs will be informed that HPV vaccination has been given after each dose. After 
the blood sample visit at month 12, GPs will be informed which HPV vaccine the participant 
received.  
 
E. Randomisation     
A computerised block randomisation list will be produced by the Statistician at CfI. Each VRN 
will be allocated blocks of sequential numbers in accordance with the block size used for 
randomisation. On recruitment to the study, each subject will be allocated, in order of 
inclusion, the next available study number by their VRN. The study number will define the 
group to which the subject is assigned and therefore the vaccine they will receive. Vaccinated 
individuals, however, will not be aware of which HPV vaccine (GardasilTM or CervarixTM) they 
will be receiving during the course of the study. Laboratory staff will be aware of the study 
number and patient initials associated with the collected samples but will not be able to link 
these data with the vaccine received nor other patient identifiers.  
 
F. Collection and testing of samples     
Four blood samples (ca. 5mL clotted blood) will be collected from each subject, at months 0, 2, 
7 and 12 of the study. One extra blood sample (ca. 30mL heparinised blood) may be collected 
at month 7 i.e. one month following the final vaccine dose. An optional self-taken lower vaginal 
sponge will also be collected on month 7. Participation in the study will not depend on whether 
the individual volunteers to give a sponge sample. 
 
Forms from appropriate Standard Operating Procedures (SOPs) will be included with samples 
to document the movement of samples between sites and laboratories. Logs of samples sent 
and received will be kept at CfI to enable the identification of any lost or delayed samples and 
provide a log of where samples are currently stored. Laboratory staff will be blinded to the 
vaccine received.  
 
Blood 
Blood sampling will be in accordance with venepuncture SOP. No more than two attempts at 
venepuncture will be made. An anaesthetic cream (EMLA or Ametop) will be offered for use on 
the intended bleeding site to minimise discomfort. At least 5ml of blood and no more than 10 
ml of blood will be taken at each sample collection point for serum generation. At month 7 (one 
month following the full regimen of GardasilTM or CervarixTM doses) an additional 30mls of 
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heparinised blood may be taken for the isolation and storage of peripheral blood mononuclear 
cells (PBMC; white blood cells).  
 
The Vaccine Research Nurse (VRN) will stick an adhesive label bearing the subject’s unique 
number onto each sample tube. She will also write the subject’s initials on each label. 
Adhesive labels bearing the subject number will be packed with the samples and sent to the 
primary receiving laboratory, which will be:  
 
FAO: Dr Simon Beddows [CSP01] 
VIA Central Specimen Reception 
Centre for Infections 
Health Protection Agency 
61 Colindale Avenue 
London NW9 5EQ 
 
VRNs will send standard 5mL blood samples taken at Months 0, 2, and 12 by Royal Mail next 
day delivery. Blood samples taken at Month 7 (standard 5mL blood plus 30mL heparinised 
blood) will be sent by courier for same day or overnight delivery, as appropriate. 
 
Blood will be processed and tested or archived according to laboratory SOPs for measurement 
of the following: 
 
i. HPV antibodies using binding and functional assays 
ii. HPV cell mediated immune responses 
 
(Optional) Lower Vaginal Self-Taken Sponge 
A self-taken lower vaginal sponge will be collected at Month 7 and sent by courier with the 
Month 7 blood samples, as above, if applicable. This sample is voluntary and refusal to take 
part will not affect further participation in the study. Instructions on how to take the sponge will 
be given by the Vaccine Research Nurse. Essentially, a sterile sponge is inserted 1-2cm into 
the lower entrance of the vagina, and the sides of the vagina are sponged. The sponge is then 
placed into transport medium and labelled with an identification sticker. These samples will be 
tested for HPV-specific antibodies generated to the vaccine.  
 
On completion of testing, samples will be archived at the Health Protection Agency, Colindale, 
where permission for this has been granted by the subject. 
 
I.   Collection of safety data 
Subjects will be asked to record daily in a health diary any local reaction (redness, swelling, 
tenderness) and give measurements if present, to take their temperature using a thermometer 
provided.  They will be asked to record any visits to a doctor – hospital or GP – as well as to 
document anything else that they think study personnel should be aware of.  
 
H.   Data records 
Vaccine Research Nurses (VRNs) will maintain their own records of all subjects enrolled in the 
study under their care. Information kept will include the surgery or school attended, vaccination 
due dates, contact details. 
 
CRFs will be provided to VRNs by CfI. CRFs will be numbered and will indicate the group to 
which the subject assigned that number has been randomised. Subjects will not be made 
aware of this information. CRF packs will comprise a series of cards relating to each clinical 
stage of the study process. Also included will be a change of circumstances card for any 
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subject whose name or address is altered during the course of their participation, and a 
completion card that will detail whether the protocol was completed or whether subjects were 
withdrawn or lost to follow-up, with appropriate details given.  
 
VRNs will complete the CRFs at each visit and these will be sent to CfI. A study database will 
be constructed at CfI to record the information collected in the CRFs. As the data is being 
entered, the CRFs will be monitored for completion errors or omissions. When such a problem 
is identified the card will be photocopied and the field for correction marked. The photocopy 
will be sent to the VRN who will make the correction, crossing out any incorrect information 
with a single line, and will sign and date the change. On return of the photocopy to CfI the 
database will be updated accordingly and the photocopy filed with the original CRF.  
 
Information from the clinical record cards will be entered at CfI into a database on a 
microcomputer. Data will be entered twice by two independent data-entry staff and will be 
verified electronically. Laboratory data will be e-mailed to the Consultant for Clinical Trials and 
imported into the database so that test results can be linked to clinical records. 
 
STATISTICAL METHODS 
Full details will be given in the statistical analysis plan produced by the Statistician. 
 
Brief description. 
The primary purpose of this study is to determine the level of neutralising antibody reactivity 
(i.e. antibodies able to prevent HPV infection of target cells in laboratory culture) against not 
only the vaccine-incorporated types (HPV 16 and 18) but also the genetically-related, non-
vaccine cancer-causing types (31, 33, 35, 39, 45, 52, 58, 59, 68). The main outcome will be 
the proportion of vaccinated individuals generating measurable antibody-mediated 
neutralisation against HPV 45 at the peak response (one month post-3rd dose; i.e. month 7). 
Further outcome measures will be the proportion of vaccinated individuals generating 
measurable antibody-mediated neutralisation against non-vaccine HR HPV types and the 
geometric mean titres for each HPV type, by vaccine and sample type, at each time point. For 
proportions exact confidence intervals will be calculated. For titres data will be logged (base 
10) and assuming normality on the log-scale 95% confidence intervals calculated. If for any 
reason data are clearly not normal then the 95% confidence interval may be calculated after 
excluding outliers (such as those individuals who fail to generate an acceptable immune 
response to vaccine-incorporated HPV types, 16 and 18). If a large proportion of the subjects 
fail to generate an acceptable response then it may not be possible to calculate geometric 
means.  
 
SAMPLE SIZE CALCULATION 
There are limited data regarding cross-reaction to non-vaccine HPV types. Clinical trials have 
not been powered to give precise estimates of protection against individual non-vaccine types, 
and where data have been reported these are commonly limited to cross-protection against 
the two next most common HPV types HPV 31 and HPV 45. Trials have estimated that 
protection against HPV 31 ranges from ~10% to 55% and against HPV 45 from ~60% to 90%; 
however, the confidence limits around these estimates are extremely wide (Paavonen et al., 
2007; Brown et al., 2007).  
 
The sample size estimates for this study are based on the assumption that the percentage of 
blood samples at month 7 with cross-reactive antibodies against HPV 31 will be between 10% 
and 55% and against HPV 45 between 25% and 90% (Giroglou et al., 2001; Combita et al., 
2002; Smith et al., 2007). Recruitment of 200 participants in each arm of the study will enable 
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us to detect the percentage of cross reactive samples at month 7 within the limits shown in the 
following table. 
 
Cross reaction 
against: 
Percentage of samples showing 
cross-reaction 
Precision of estimate of the percentage 
of samples showing cross-reaction 
HPV 31 10% +/- ~4% 55%, +/- ~7% 
HPV 45 25% +/- ~6% 90% +/- ~4% 
 
When comparing the two vaccines, the population percentages which give rise to an 80% or 
more chance that observed percentages in the two study arms will be found to be significantly 
different at the 5% level are shown below. For example, we would have an 80% chance of 
detecting as significantly different, 50% versus 35% cross-reactive antibodies in the two 
populations. 
 
Percentage of samples with 
cross-reactive antibodies in 
Population 1 
Percentage of samples with cross-reactive antibodies in 
Population 2 (percentages that give rise to an 80% or more 
chance that the observed percentages in the two study arms will 
be found to be significantly different) 
10% ≤2.7% ≥20.5% 
25% ≤13.5% ≥38.5% 
50% ≤35.7% ≥64.3% 
75% ≤61.5% ≥86.5% 
90% ≤79.5% ≥97.3% 
 
DATA ANALYSIS AND PRESENTATION      
Data analysis will be undertaken by the Immunisation Department Statistician and members of 
the Clinical Trial Team where appropriate. The results of the study will be reported to the 
Department of Health, the Joint Committee on Vaccination and Immunisation and a paper 
submitted for publication in a peer-reviewed journal. Further details will be in the statistical 
analysis plan. 
 
COMPLIANCE WITH GUIDELINES 
The study will be conducted in accordance with the ICH GCP (1996) guidelines, the 
Declaration of Helsinki (2008), and the EU Clinical Trial Directive (2004). Approval for the 
study will be sought from the appropriate research ethics committee(s).  The HPA will obtain a 
Eudract registration number for the trial. The HPA will then apply for CTA status for the study 
from the Medicines and Health Care Products Agency (MHRA). 
 
LABORATORY TESTING OF VACCINES     
All batches marketed in the UK and in routine use at the time of the study will have been 
released by EC Official Control Authority Batch Release process and tested according to 
documented guidelines by an Official Medicines Control Laboratory. The National Institute for 
Biological Standards and Control (NIBSC) or the National Institute for Public Health and the 
Environment (RIVM; The Netherlands) will have tested and reviewed the summary batch 
protocols for GardasilTM and NIBSC or the Scientific Institute of Public Health (SIPH; Belgium) 
will have tested and reviewed the summary batch protocols for CervarixTM. No additional 
laboratory testing of the vaccines supplied for the study will be necessary. 
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INDEMNITY ARRANGEMENTS 
Product liability will apply as both vaccines are licensed for use in the UK. The Sponsor for this 
study will be the Health Protection Agency, and indemnity will be provided under the NHS 
indemnity scheme wherein cover for any negligent harm caused by our staff as a result of study 
participation and where justified, an ex gratia payment for any non-negligent harm, will be 
provided as appropriate.  
 
STUDY PERSONNEL         
Please see Appendix 2 
 
TARGET DATES        
Recruitment started in September 2009 and is anticipated to end in autumn 2010.The final 
dose of the vaccine (Month 6) will be given spring 2010. The trial will last 12 months. The final 
samples are expected to be collected between autumn 2011. 
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Appendix 1: 
 
 
Patient Information: 
Pre-information leaflet, Full information 
leaflet, Consent form, Introduction letter, GP 
information letter 
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HPA headed paper 
 
HPV Vaccine Study 
 
• Your GP / School [will insert in final letter as appropriate] is working 
with us to carry out a study of two licensed vaccines against HPV, which 
is the virus that can cause cervical cancer  
 
• We would like to invite you to take part in this study as you are a female 
aged between 12 and 15 years 
 
• We would like your permission for a Vaccine Research Nurse to contact 
you for an informal discussion and to give you further information about 
this study.  
 
• Please note that we have not been given your name and address details. 
 
 If you would like further information please complete the slip at the 
bottom of this leaflet and return in the envelope provided. 
 
 If you do not want a Vaccine Research Nurse to contact you, you 
need do nothing further. This will not affect your routine medical care. 
 
Thank you 
 
------------------------------------------------------------------------------ 
I would like to receive further information about this study and I am happy for 
a Vaccine Research Nurse to contact me. 
 
Name:             
Address:______________________________________________ 
             
Tel No:     Mobile no.       
Preferred time to be contacted:________________________________ 
 
GP Surgery I attend: ____________________________________ 
School I attend [to be inserted if appropriate]: _________________ 
       (HPV CSP01 study) 
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GP / School covering letter for pre information leaflet 
 
 
ON SURGERY / SCHOOL HEADED PAPER 
 
 
 
 
 
 
 
Dear Patient / Student, 
 
 
 
We are working with the Health Protection Agency* on a study of two HPV vaccines. HPV 
is the virus that has been shown to cause cervical cancer. 
 
As you are a female aged between 12 and 15 years, we are sending you this letter and a 
leaflet that gives a brief summary of the study and how to receive more information. 
 
Please note that the HPA does not have your name or address details and will only 
contact you if you request further information.  
 
 
 
Yours sincerely  
 
 
 
 
 
 
Signature & name [GP or School representative as appropriate] 
 
*The Health Protection Agency (HPA) is an independent body funded by the government that protects the 
health and well-being of the population. The Agency plays a critical role in protecting people from infectious 
diseases and in preventing harm when hazards involving chemicals, poisons or radiation occur. 
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Patient Information Leaflet 
 
HPV Vaccination Study 
 
Full title: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls 
receiving CervarixTM or GardasilTM Human Papillomavirus vaccines 
 
Study code: HPV CSP01 
 
 
Your doctors’ surgery or school is taking part in a study with the Health Protection Agency of two 
licensed HPV vaccines, one of which is being used in the routine UK schedule. Before you decide if 
you would like to join this study you need to understand the reasons the research is being done 
and what it would involve. Ask us if there is anything that is not clear or if you would like more 
information. We encourage you to discuss this leaflet with your parents and others to help you with 
your decision. It is important to take time to decide whether or not you wish to take part.  
 
Part 1 tells you the purpose of the study and what it would involve  
 
Part 2 gives you more detailed information about the conduct of the study 
 
PART 1 
 
What is the purpose of the study? 
HPV is a virus that can cause cervical cancer in some women. There are many strains of HPV. 
About 12 HPV strains can cause cervical cancer, two strains of HPV can cause genital warts and 
many other HPV strains cause no disease. Around 70% of cervical cancers are caused by just two 
strains (known as HPV 16 and HPV 18). Many of the other strains that can cause cervical cancer 
are very similar to these two strains.  
 
Two vaccines against HPV, called CervarixTM and GardasilTM, have recently been licensed in the 
UK. These vaccines protect against infection with HPV 16 and HPV 18 (the strains that cause 70% 
of cervical cancers).  GardasilTM also protects against the two strains (HPV 6 and HPV 11) that can 
cause genital warts. The study will assess both vaccines (CervarixTM and GardasilTM). 
 
We are interested in whether the HPV vaccines will protect against infection with other strains 
similar to those included in the vaccine. To do this, we will look at the antibodies produced by your 
body after vaccination and use these in laboratory experiments to see which strains of virus they 
work against. Antibodies are the substances in your blood that help you fight infections. Some 
antibodies, called mucosal antibodies, are found on the outside of the body (such as the genitals 
and mouth) and protect against infection at those sites. We will examine white blood cells after the 
third dose of vaccine: it is these cells which co-ordinate the production of antibodies in the body.  
 
Is HPV vaccine routinely given in the UK? 
Since September 2008, HPV vaccine is being given routinely to 12-13 year old girls (school year 
8). The vaccine being used is CervarixTM. Older girls aged up to 18 years will also be offered the 
vaccine in a catch-up programme.  Both HPV vaccines are licensed for use in the UK. If you do not 
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wish to take part in this study then you will still be able to have the CervarixTM HPV vaccine in the 
future.  Most people will be offered the vaccine through their school. Your local primary care trust 
(PCT) will let you know when you are due to be given the vaccine.  
 
How effective are the HPV vaccines? 
Both HPV vaccines are 99% effective in preventing pre-cancerous cervical abnormalities caused 
by the HPV types 16 and 18. Pre-cancerous abnormalities can lead to cervical cancer if left 
untreated. HPV 16 and 18 cause about 70% of cervical cancers. HPV vaccines work by preventing 
initial HPV infection. HPV is sexually transmitted and is extremely common: about 40% of 20-25 
year old women have HPV infection.  
 
The vaccines have been shown to provide high levels of protection for at least six years. It is likely 
that protection will last much longer than this however as antibody levels in vaccinated women in 
clinical trials have remained very high.  
 
For further information please visit: www.immunisation.nhs.uk/Vaccines/HPV 
 
Vaccine Safety 
Both HPV vaccines have been shown to be safe in clinical trials and are licensed for use in 
Europe. In clinical trials alone 60,000 women have received HPV vaccine and HPV vaccination is 
now recommended for girls in many developed countries.  
 
As with most vaccines, the most common side effect is mild to moderate swelling, redness and 
pain at the site where the injection is given. Other mild side effects, such as slightly raised 
temperature, sickness, dizziness, diarrhoea and muscle aches have been reported. Very rarely, as 
with most vaccines, some people have an allergic reaction soon after immunisation. The Vaccine 
Research Nurse will know how to treat this.  
 
For further information please visit: www.immunisation.nhs.uk/Vaccines/HPV 
 
Can women take part if they are pregnant? 
You will be asked by the Vaccine Research Nurse (VRN) about the possibility that you may be 
pregnant. If you are pregnant or breast-feeding you cannot take part in this study. This is because 
HPV vaccination for pregnant women has not been well studied. Whilst you are in this study, if you 
are having sex, you must use an effective method of contraception to reduce the risk of pregnancy. 
If you would like, you can discuss this with a nurse/doctor at your GP practice. 
 
Will I benefit from taking part in this study? 
You may not benefit from taking part in this study as you may be given the same vaccine as most 
other girls in the UK (CervarixTM). However you may benefit as you may be given GardasilTM. 
GardasilTM is licensed in the UK but is not being used for most girls because it is more expensive. 
Both vaccines will protect you from infection with two types of HPV that cause 70% of cervical 
cancers. If you are given GardasilTM you will also be protected against genital warts. By taking part 
in this study you will benefit girls and women in the future because the results from this study will 
help decide future vaccination policy from the Department of Health. 
 
Are there any disadvantages if I take part? 
If you take part in this study you will have 4 blood samples taken. Having a blood sample taken 
may occasionally result in a bruise, which will usually disappear after a couple of days. You will 
also be asked for an entirely voluntary self-taken lower vaginal sample. You will be able to take this 
sample in private and it should not cause discomfort. If you do not wish to provide this sample you 
can still take part in the study. 
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Do I have to take part? 
No. You can choose whether you would like to take part in this study. If you decide to take part after 
discussion with your VRN, you and your parent/guardian will be asked to sign a consent form. Taking 
part in this study is entirely voluntary, you can stop at any time without giving a reason, and your 
VRN will be happy to discuss any further vaccinations that should be given by your GP surgery or at 
school.  
 
Why have I been invited to take part? 
We wish to examine the body’s responses to the HPV vaccines CervarixTM and GardasilTM to 
determine the likelihood that the current vaccines will protect against other cancer-causing strains 
of HPV that are not present in the vaccines. We would like to invite you to take part in a study that 
will enrol 400 girls in Hertfordshire and Gloucestershire. Girls aged 12 to 15 years at your GP 
surgery or school will be invited to take part as these girls are closest in age to those who will 
usually be given the HPV vaccine in the UK. 
 
What will happen to me if I take part? 
If you choose to take part you will receive the HPV vaccine and be asked to give 4 blood samples 
and, if you agree, provide one self-taken lower vaginal sample. The study will involve 6 visits to see 
the VRN at your GP surgery or school over 12 months (as shown in the table below). The first 
appointment will take about an hour and the rest about half an hour each. We will inform your GP 
that you are taking part in the study. 
 
 
1. HPV vaccinations 
All people taking part in the study will be given three doses of HPV vaccine at months 0, 1 and 6 of 
the study (highlighted in yellow in the table, above). All vaccines will be given at your GP surgery or 
school by your VRN. There are two groups in this study, girls in one group will be given GardasilTM 
and girls in the other group will be given CervarixTM.  A computer programme will decide randomly 
(like tossing a coin) which group you are in. This random draw helps us make sure the groups are 
similar when we are comparing the two HPV vaccines. 
  
2. Blood Samples 
Blood samples will be taken at four visits (months 0, 2, 7 and 12 highlighted in blue on the table 
above).  At each visit, your VRN will offer you some cream to numb the skin and will take one tube 
(5-10mls) of blood. At month 7, a larger tube (30ml) may also be filled with blood. The blood samples 
will be used to measure blood antibodies and cells and compare them between the two groups.  
 
3. Self-taken lower vaginal sample 
We would like you to provide one self-taken lower vaginal sponge at month 7 (highlighted in green on 
the table above).  If you do not wish to provide this sample you can still take part in the study.  If you 
would like to decide nearer to the time (month 7), you can still take part in the study. If you do decide 
to provide this sample, the VRN will give you the self-taken sample kit and talk to you about the 
sample in months 6-7. You will be able to take the sample in private and it should not cause any 
discomfort. This sponge sample will be very useful because it will let us look at the mucosal 
antibodies. These are the antibodies that are outside the blood at the genital surface and will be the 
body’s first defence against HPV infection.   
The consent form includes consent to provide a lower vaginal sponge sample. If you agree to provide 
this sample please initial the box. If you initial the box and then change your mind and do not wish to 
provide the sample, please tell the VRN. If you do not initial the box and later change your mind and 
wish to provide a lower vaginal sponge sample, please talk to your VRN. 
Activity Month 
Vaccination (CervarixTM or GardasilTM) 0 1 2 3 4 5 6 7 8 9 10 11 12 
Blood taken by Vaccine Research Nurse 0 1 2 3 4 5 6 7 8 9 10 11 12 
Voluntary self-taken lower vaginal sponge 0 1 2 3 4 5 6 7 8 9 10 11 12 
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4. Health diary and records 
We will ask you to complete a health diary to record how well you have felt after each vaccination 
(e.g. any problems, reactions at injection site, temperature, if you have seen a doctor, etc). Your 
VRN will explain how to fill in the diary and will show you how to use the thermometer you will be 
given. We will review your medical notes before each vaccination to collect information about any 
illnesses or medicines prescribed. We may then contact your doctor for further information. If you 
have a serious illness and see the GP or are admitted to hospital, please inform the doctor that you 
are taking part in this study. Regardless of the illness or reason for admission, please then let us 
know by telephoning your VRN.  
 
The samples collected for this study and the health diary would not be part of your routine care if you 
do not take part in the study. 
 
At the end of the study, we will inform you of the overall results of the study and which vaccine you 
received. We will not tell you or anyone else your individual results. 
 
Expenses and payments 
If you incur any costs when seeing the VRN (to have the vaccine or give samples) which you wish 
to claim back, please ask your VRN for a claim form and we will reimburse you. 
 
Will my taking part in the study be kept confidential? 
Yes, we will follow ethical and legal practice and all information will be handled in confidence. For 
further details on confidentiality, see Part 2 of this information sheet. 
 
What happens when the research study stops? 
When the study ends we will tell you which of the HPV vaccines you were given. If you completed 
the study, you will not need to have the HPV vaccine when you are offered it through the PCT 
(probably through your school).  If you stop taking part in the study early then we will let your GP 
know as you will need to complete your vaccination under the national HPV immunisation 
programme.  
 
After we have completed this study, there may be small amounts of your samples remaining. We 
would like to be able to use these samples for other studies that will help us understand better how 
vaccines work. Before we do this we will remove your name and any other information from which 
you could be identified.  If you are happy for us to use your left-over samples for other studies, 
please consent to this on the consent form. If you do not wish your left-over samples to be kept for 
future studies, you can still take part in this study.  
 
 
Part 1 summary: 
• You will be given the usual course of three HPV vaccinations, have four sets of 
blood samples taken plus one optional self-taken lower vaginal sample 
• The study will take a year and involve 6 visits to the Vaccine Research Nurse – 
either at your GP or School. 
• The vaccines we are using are licensed for use in the UK and Europe 
 
If the information in Part 1 has interested you and you are considering taking part 
please read the additional information in Part 2 before making any decision. 
 
This is the end of Part 1 
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PART 2 
 
What if relevant new information becomes available? 
If relevant new information becomes available or the study is to be stopped for any reason we will 
let you know, as well as give you and your GP information about your continuing care if 
appropriate. 
 
What will happen if I do not want to carry on in the study? 
You can withdraw from the study at any time without affecting your routine care. We will let your 
GP know so you can complete your vaccination under the national HPV immunisation programme.   
 
If you withdraw you would need to decide if you want samples collected from you to be destroyed. 
If you would like them to be destroyed you would need to inform us in writing. We would retain any 
information collected to that point in case we needed to reach you at some point in the future 
based on the outcome of the study. 
 
What if there is a problem? 
 
• Complaints 
If you have a concern about any aspect of this study, you can contact the study organiser, Prof 
Elizabeth Miller on 0208 327 7434, who will do her best to answer your questions. If you remain 
unhappy and wish to complain formally then you can do this through the NHS Complaints 
Procedure, details of which can be obtained at www.nhs.uk or by phoning 0845 601 3012 
 
• Harm 
The vaccines that will be given in this study are licensed for use in the UK. In the event that 
something does go wrong and you are harmed during the research and this is due to someone’s 
negligence then you may have grounds for legal action for compensation against the Health 
Protection Agency but you may have to pay your legal costs. The National Health Service 
complaints mechanism will still be available to you. Where justified, an ex gratia payment for any 
non-negligent harm may be made.  
 
Will my participation in the study be kept confidential? 
Under the data protection laws, you have a right know how your personal data from this trial will be 
used so you can understand what information will be collected and who will have access to it. We 
will collect only sufficient data to enable us to conduct the study and answer the study questions. 
The people who require data will only be given information about you that is necessary for their 
task, for example, people analysing samples and study results will not be told your name or 
address. The only people who may be given access to study information will be employees or 
agents of the Health Protection Agency, the Department of Health or regulatory authorities who 
may wish to check the study is being carried out within the appropriate guidelines.  
 
The data will only be used for the purposes of this study and any data released outside the above 
group will be anonymised. This means that your name and address will be removed.  Data will be 
stored in secure Health Protection Agency facilities and will be disposed of within clinical trial 
guidelines after the appropriate time period which may be a number of years.  
 
Will my GP be involved in this study? 
We will write to your GP to let him/her know that you are taking part in the study. During the study, 
your GP will not be involved in giving the vaccine or taking samples – the VRN will do these tasks.  
 
What will happen to any samples I give? 
The samples will be labelled with your study number and initials but not your name. The samples 
will be tested in laboratories and results sent to the Health Protection Agency, Centre for Infections 
where they will be linked with information about you.  
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Will any genetic tests be done? 
No genetic tests will be carried out on your samples.  
 
What will happen to the results of the research study? 
We plan to publish the results in a medical journal which will be accessible to the public. The 
results of the study will also be reported to the Department of Health to help with planning national 
vaccination programmes in the future. You will not be named in any report or publication and it will 
not be possible for anyone to work out that you took part in the study.  
 
Who is organising and funding the research? 
The study is funded by the UK Department of Health and is being organised by the Immunisation 
Department of the Health Protection Agency. The Health Protection Agency (HPA) is an 
independent body that protects the health and well-being of the population. The Agency plays a 
critical role in protecting people from infectious diseases and in preventing harm when hazards 
involving chemicals, poisons or radiation occur.  
 
Who reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee to protect the safety, rights, well being and dignity of individuals. This study has been 
reviewed and given favourable opinion by the XXXX Research Ethics Committee (Tel No. 
xxxxxxxxxxx). The Research Ethics Committee reference number for this study is… 
 
Further information and contact details: 
If you have any questions, you can ask your VRN or contact the organisers, Professor Elizabeth 
Miller on 0208 200 6868 or Dr Chee Yung 020 8327 7603. 
 
Further information about our trials programme including links to the organisations reviewing 
research and the guidance we follow can be found at www.hpa.org.uk and typing clinical trials into 
the search bar.  
 
We do hope that you will take part in this study. Your contribution would be an important step 
towards the continual improvement of vaccine policy in the UK. You may be invited to take part in 
future studies with us by virtue of the surgery you attend. We reassure you that invitations for 
future studies will not be because of anything to be concerned about from results of this study. 
 
Sticker with Vaccine Research Nurse Name and Contact Details 
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When completed, 1 copy for participant; 1 copy for researcher site file (and scanned into medical notes) and 
original to be held at Centre for Infections 
 
 
 
 
CONSENT FORM 
 
Centre:   Gloucester / Hertfordshire    (delete as appropriate) 
Study Number: HPV CSP01 
 
Patient Identification Number for this trial: 
 
Title of Project: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls 
receiving CervarixTM or GardasilTM Human Papillomavirus vaccines 
 
Name of Chief Investigator: Professor Elizabeth Miller 
 
 
Patient/Student 
please initial box 
Parent/Guardian 
please initial 
box 
1. I confirm that I have read and understand the information sheet 
dated.................... (version............) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
  
2. I understand that my participation is voluntary and that I am/my daughter is 
free to withdraw at any time without giving any reason, without my/her medical 
care or legal rights being affected. 
  
3. I understand that relevant sections of my/my daughter’s medical notes and 
data collected during the study, may be looked at by individuals from the Health 
Protection Agency, from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my/her records. 
  
4. I agree to my/my daughter’s GP being informed of my/my daughter’s 
participation in the study 
 
  
5. I agree to take/my daughter taking part in the above study. 
 
  
6. I agree to provide /my daughter providing a self-taken lower vaginal sponge 
sample. [This is optional – you/she may still take part in the study without 
providing this sample.] 
  
7. I consent to the use of any residual samples from me/my daughter being 
used within the Health Protection Agency, once anonymised, to improve the 
understanding of vaccines and how they work. [This is optional – you/she can 
still take part in the study if you do not give consent for this. If you do not wish 
samples to be stored please strike through this section and do not initial the 
box]. 
  
 
 
             
Patient / Student (Participant)   Date    Signature 
 
 
             
Parent / Guardian of Patient  Date    Signature 
 
 
             
Person taking consent   Date    Signature 
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ON SURGERY / SCHOOL HEADED PAPER 
 
 
 
 
 
 
 
Dear Patient / Student 
 
 
I am the Vaccine Research Nurse at your doctor’s surgery / school [will insert as 
appropriate].  Thank you for requesting information about the study of vaccines taking 
place at the surgery. Please find enclosed a leaflet that gives full details of the study and 
what would be involved should you wish to enrol.  
 
I will try to contact you by telephone shortly to see if you would like to discuss any aspect 
of the study or have any queries.  Participation in the study is entirely voluntary.  If you 
decide not to participate, it will in no way affect your routine care.  
 
If you would like to take part in the study you can also call me on the telephone numbers 
listed at the bottom of this page. (If you prefer to decline you need take no action, or your 
can call me to let me know you would like your name removed form my contact list) I look 
forward to hearing from you and thank you for your time and consideration. 
 
 
Yours sincerely  
 
 
VACCINE RESEARCH NURSE  
CONTACT DETAILS 
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ON HPA HEADED PAPER 
HPV vaccine study         GP Information Leaflet 
A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving 
CervarixTM or GardasilTM Human Papillomavirus vaccines (Study No.: HPV CSP01) 
 
Dear Doctor        Study No. HPV CSP01      
Re : ___________________________________________ 
 
A study to evaluate the response to licensed HPV vaccines is being conducted in your health district. This 
study seeks to assess antibody responses to these vaccines with the schedule below, including assessing 
any cross-protection that the vaccines may afford against HPV types not included in the vaccines. Schedule 
flexibility has been highlighted for GardasilTM (Merck & Co. Inc., #9682307) in which a change of 2nd dose 
from month 2 to 1 can be tolerated. To facilitate a comparison of immune responses elicited to both vaccines 
the schedules have been synchronized, where each individual will be vaccinated at months 0, 1 & 6. 
 
 Timepoint (months) 
 
GROUP 
 
 
0 
 
1 
(-2 days / 
+2 weeks) 
 
2 
(+/- 1 week) 
 
6 
(+/- 1 week) 
 
7 
(+/- 1 week) 
 
12 
(+/- 1 week) 
 
 
1 
(n=200) 
 
CervarixTM 
 
Blood 
sample 
 
CervarixTM 
 
 
 
 
Blood 
sample 
 
CervarixTM 
 
 
 
 
Samples (incl. 
extra blood 
and optional 
sponge) 
 
 
 
Blood 
sample 
 
 
2 
(n=200) 
 
GardasilTM 
 
Blood 
sample 
 
 
GardasilTM 
 
 
 
 
Blood 
sample 
 
GardasilTM 
 
 
 
Samples (incl. 
extra blood 
and optional 
sponge) 
 
 
 
Blood 
sample 
 
“Samples” denotes the collection of: 
• 5mL blood (clotted) at Month 0, 2, 7 and 12 
• 20-30mL blood (heparinised) at Month 7 may be taken 
• (Optional) self-collected lower vaginal sponge on Month 7 
 
The above person is enrolled in this study and the 1st dose of vaccine given on ____/____/____ .   
 
If you would like further information on this study, please contact the study organisers listed below: 
 
Prof Elizabeth Miller   Tel: 020 8327 7434 
Head, Immunisation Division 
CfI, Health Protection Agency 
 
Dr Chee Yung    Tel: 020 8327 7603 
Consultant for Clinical Trials 
CfI, Health Protection Agency 
Activity Month 
Vaccination (CervarixTM or GardasilTM) 0 1 2 3 4 5 6 7 8 9 10 11 12 
Blood taken by Vaccine Research Nurse  0 1 2 3 4 5 6 7 8 9 10 11 12 
Voluntary self-taken lower vaginal sponge 0 1 2 3 4 5 6 7 8 9 10 11 12 
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Investigators 
 
Prof Elizabeth Miller 
Head – Immunisation Department  
CfI, Health Protection Agency 
61 Colindale Ave 
London NW9 5EQ 
 
Telephone: 0208 327 7430 
Fax: 0208 200 7868 
 
Co-ordinating Centre 
 
Dr Simon Beddows 
Scientific Advisor 
 
Mr Nick Andrews 
Statistical Advisor 
 
Mr Tom Nichols 
Trial statistician 
 
Pauline Kaye 
Data Manager 
 
Dr Chee Yung 
Consultant for Clinical Trials 
 
Joan Vurdien 
Finance Officer 
 
Immunisation Division 
Communicable Disease Surveillance Centre 
Health Protection Agency  
61 Colindale Avenue 
London 
NW9 5EQ 
 
Tel: 0208 200 6868 
Fax: 0208 200 7868 
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Severe adverse events in post vaccination period 
Any of the following local or systemic symptoms will be defined as a severe adverse event 
and will be reported within 24 hours by the Vaccine Research Nurse to the co-ordinating 
centre, at CfI or Gloucester: 
 
LOCAL: An extensive area of redness and swelling at the site of injection which 
becomes indurated and involves most of the circumference of the arm. 
 
SYSTEMIC: Fever > 39.5oC within 48 hours of vaccination; anaphylaxis; bronchospasm; 
laryngeal oedema; generalised collapse; prolonged unresponsiveness. 
 
Serious adverse events (SAEs) 
Reporting of SAEs will be conducted in line with the relevant HPA Immunisation 
Department SOP. 
 
Any of the following conditions occurring during the study period will be considered a 
serious event. Subjects will be asked to contact the Vaccine Research Nurse if these 
occur and this will then be reported within 24 hours by the Vaccine Research Nurse to the 
co-ordinating centre, at CfI: 
 
• Death 
 
• Non-elective hospitalisation 
 
• Any event leading to sequelae 
 
• Life threatening event 
 
ICH GCP guidelines for reporting SAEs will be followed:  
 
Subjects will be asked to contact their Vaccine Research Nurse if they have a severe or 
serious adverse event during the study period. Vaccine Research Nurses will inform the 
co-ordinating centre, CfI, of such events within 24 hours. The VEC SAE form will be 
reviewed by the medic at CfI. Action will then be taken depending on whether the SAE is 
deemed to be related to the vaccine or if it is considered a SUSAR 
The causal relationship between severe/serious events and vaccination will be categorised 
by the investigators, after appropriate specialist consultation where necessary, as one of 
the following: related; probable; possible; remote or unrelated. Events will be graded by 
the clinical investigator as mild, moderate or severe.  
 
Suspected Serious Adverse Reactions will (SSARs) be reported through the annual safety 
report.  
 
All Suspected Unexpected Serious Adverse Reactions (SUSARs) will be reported by the 
HPA to the MHRA and the ethics committee within seven days for life threatening/fatal 
reactions, and within 15 days for all other severe unexpected reactions. SUSARs will be 
reported to the MHRA using the CIOMS (Council for International Organisations of Medical 
Sciences) form.  The form will include the EudraCT number, CTA number, protocol 
number and study name.  
 
Manufacturers will be informed of a severe or serious event using a standard adverse 
event report form where relation to vaccination is suspected by study medics.  
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SITE FILE INDEX 
A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving 
CervarixTM or GardasilTM Human Papillomavirus vaccines (study code HPV CSP01) 
 
1. Protocol  
An overview of the objectives and design of the trial, and the selection and recruitment of 
subjects. Details of the organisations involved and the procedures used in the study. 
Amendments made during the trial will be forwarded to the site for inclusion in this file. 
 
This section will also include: Investigator agreement 
Documents the agreement of personnel involved in the trial to conduct the trial according 
to the protocol – signed protocol approval forms. 
 
2. Patient information  
A copy of the documentation given to patients prior to and during the study giving 
information on the conduct of the trial and the safety precautions. This includes consent 
forms and advertisements for recruitment of subjects. 
 
3. Product information 
As licensed vaccines will be used in this study, copies of the product inserts for each 
vaccine to be administered will made available to the VRNs for reference 
 
4. Trial approvals 
Details of the approval of the trial by appropriate ethics and committees and coverage by 
indemnity agreements in the event of any trial-related incidents. This shows the trial is in 
compliance with the applicable regulatory requirements. 
 
5. Drug accountability 
Documents instructions needed to ensure proper storage, packaging, dispensing and 
disposition of trial related materials. Nobody in the practice should need to become 
involved in this aspect of the trial - this section is for information only. 
 
6. Monitoring visit log 
Documentation of site visits by, and findings of, the trial monitor.  
 
7. Signature sheet 
A record of all persons involved in conducting the trial who may have signed documents in 
the course of their involvement at this site as well as centrally to the HPA. 
 
8. Communication for specific sites 
Documentation of communication between the HPA and this site. 
 
9. Investigator delegation list 
Contact details for various possible scenarios. 
 
This section will also include: CVs 
Detailing the qualifications and experience of all clinical personnel involved in the trial 
relevant to this site. 
 
10. Subject log 
A confidential register of all the subjects in the trial at this site and their dates of 
vaccination. (Logged chronologically by subject number). 
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This section will also include: Consent forms 
The original consent forms signed by the parent, subject (where appropriate) and Vaccine 
Research Nurse prior to the enrolment of the subject into the study. 
 
 
 
 
Additional information 
The following documents are held centrally at CfI and copies are available to personnel 
involved in the study on request: 
 
• Membership lists of ethics committees 
• Clinical research agreements 
• Full indemnity documentation 
• Vaccine tracking forms 
• Study reports for ethics committees, HPA and Department of Health 
• Any papers published as a result of the study 
 
 
If you would like copies of any of these documents please contact Clinical Trials Admin 
Team, at the CfI on 020 8327 7471. 
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WORLD MEDICAL ASSOCIATION 
DECLARATION OF HELSINKI 
 
Ethical Principles for Medical Research Involving Human Subjects 
Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the: 
29th WMA General Assembly, Tokyo, Japan, October 1975 
35th WMA General Assembly, Venice, Italy, October 1983 
41st WMA General Assembly, Hong Kong, September 1989 
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996 
52nd WMA General Assembly, Edinburgh, Scotland, October 2000 
53rd WMA General Assembly, Washington 2002 (Note of Clarification on paragraph 29 added) 
55th WMA General Assembly, Tokyo 2004 (Note of Clarification on Paragraph 30 added) 
59th WMA General Assembly, Seoul, October 2008 
 
A. INTRODUCTION 
 
1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical 
principles for medical research involving human subjects, including research on identifiable human material 
and data. The Declaration is intended to be read as a whole and each of its constituent paragraphs should 
not be applied without consideration of all other relevant paragraphs. 
 
2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants in 
medical research involving human subjects to adopt these principles. 
 
3. It is the duty of the physician to promote and safeguard the health of patients, including those who are 
involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment of 
this duty. 
 
4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient will 
be my first consideration,” and the International Code of Medical Ethics declares that, “A physician shall act 
in the patient's best interest when providing medical care.” 
 
5. Medical progress is based on research that ultimately must include studies involving human subjects. 
Populations that are underrepresented in medical research should be provided appropriate access to 
participation in research. 
 
6. In medical research involving human subjects, the well-being of the individual research subject must take 
precedence over all other interests. 
 
7. The primary purpose of medical research involving human subjects is to understand the causes, 
development and effects of diseases and improve preventive, diagnostic and therapeutic interventions 
(methods, procedures and treatments). Even the best current interventions must be evaluated continually 
through research for their safety, effectiveness, efficiency, accessibility and quality. 
 
8. In medical practice and in medical research, most interventions involve risks and burdens.  
 
9. Medical research is subject to ethical standards that promote respect for all human subjects and protect 
their health and rights. Some research populations are particularly vulnerable and need special protection. 
These include those who cannot give or refuse consent for themselves and those who may be vulnerable to 
coercion or undue influence. 
 
10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving 
human subjects in their own countries as well as applicable international norms and standards. No national 
or international ethical, legal or regulatory requirement should reduce or eliminate any of the protections for 
research subjects set forth in this Declaration. 
 
B. PRINCIPLES FOR ALL MEDICAL RESEARCH 
 
11. It is the duty of physicians who participate in medical research to protect the life, health, dignity, integrity, 
right to self-determination, privacy, and confidentiality of personal information of research subjects. 
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12. Medical research involving human subjects must conform to generally accepted scientific principles, be 
based on a thorough knowledge of the scientific literature, other relevant sources of information, and 
adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research 
must be respected. 
 
13. Appropriate caution must be exercised in the conduct of medical research that may harm the 
environment. 
 
14. The design and performance of each research study involving human subjects must be clearly described 
in a research protocol. The protocol should contain a statement of the ethical considerations involved and 
should indicate how the principles in this Declaration have been addressed. The protocol should include 
information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest, 
incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a 
consequence of participation in the research study. The protocol should describe arrangements for post-
study access by study subjects to interventions identified as beneficial in the study or access to other 
appropriate care or benefits. 
 
15. The research protocol must be submitted for consideration, comment, guidance and approval to a 
research ethics committee before the study begins. This committee must be independent of the researcher, 
the sponsor and any other undue influence. It must take into consideration the laws and regulations of the 
country or countries in which the research is to be performed as well as applicable international norms and 
standards but these must not be allowed to reduce or eliminate any of the protections for research subjects 
set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher 
must provide monitoring information to the committee, especially information about any serious adverse 
events. No change to the protocol may be made without consideration and approval by the committee. 
 
16. Medical research involving human subjects must be conducted only by individuals with the appropriate 
scientific training and qualifications. Research on patients or healthy volunteers requires the supervision of a 
competent and appropriately qualified physician or other health care professional. The responsibility for the 
protection of research subjects must always rest with the physician or other health care professional and 
never the research subjects, even though they have given consent. 
 
17. Medical research involving a disadvantaged or vulnerable population or community is only justified if the 
research is responsive to the health needs and priorities of this population or community and if there is a 
reasonable likelihood that this population or community stands to benefit from the results of the research. 
 
18. Every medical research study involving human subjects must be preceded by careful assessment of 
predictable risks and burdens to the individuals and communities involved in the research in comparison with 
foreseeable benefits to them and to other individuals or communities affected by the condition under 
investigation. 
 
19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first 
subject. 
 
20. Physicians may not participate in a research study involving human subjects unless they are confident 
that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must 
immediately stop a study when the risks are found to outweigh the potential benefits or when there is 
conclusive proof of positive and beneficial results. 
 
21. Medical research involving human subjects may only be conducted if the importance of the objective 
outweighs the inherent risks and burdens to the research subjects. 
 
22. Participation by competent individuals as subjects in medical research must be voluntary. Although it 
may be appropriate to consult family members or community leaders, no competent individual may be 
enrolled in a research study unless he or she freely agrees. 
 
23. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their 
personal information and to minimize the impact of the study on their physical, mental and social integrity. 
 
24. In medical research involving competent human subjects, each potential subject must be adequately 
informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations 
of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, 
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and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to 
participate in the study or to withdraw consent to participate at any time without reprisal. Special attention 
should be given to the specific information needs of individual potential subjects as well as to the methods 
used to deliver the information. After ensuring that the potential subject has understood the information, the 
physician or another appropriately qualified individual must then seek the potential subject’s freely-given 
informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent 
must be formally documented and witnessed.  
 
25. For medical research using identifiable human material or data, physicians must normally seek consent 
for the collection, analysis, storage and/or reuse. There may be situations where consent would be 
impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In 
such situations the research may be done only after consideration and approval of a research ethics 
committee. 
 
26. When seeking informed consent for participation in a research study the physician should be particularly 
cautious if the potential subject is in a dependent relationship with the physician or may consent under 
duress. In such situations the informed consent should be sought by an appropriately qualified individual who 
is completely independent of this relationship. 
 
27. For a potential research subject who is incompetent, the physician must seek informed consent from the 
legally authorized representative. These individuals must not be included in a research study that has no 
likelihood of benefit for them unless it is intended to promote the health of the population represented by the 
potential subject, the research cannot instead be performed with competent persons, and the research 
entails only minimal risk and minimal burden. 
 
28. When a potential research subject who is deemed incompetent is able to give assent to decisions about 
participation in research, the physician must seek that assent in addition to the consent of the legally 
authorized representative. The potential subject’s dissent should be respected. 
 
29. Research involving subjects who are physically or mentally incapable of giving consent, for example, 
unconscious patients, may be done only if the physical or mental condition that prevents giving informed 
consent is a necessary characteristic of the research population. In such circumstances the physician should 
seek informed consent from the legally authorized representative. If no such representative is available and if 
the research cannot be delayed, the study may proceed without informed consent provided that the specific 
reasons for involving subjects with a condition that renders them unable to give informed consent have been 
stated in the research protocol and the study has been approved by a research ethics committee. Consent to 
remain in the research should be obtained as soon as possible from the subject or a legally authorized 
representative. 
 
30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of 
research. Authors have a duty to make publicly available the results of their research on human subjects and 
are accountable for the completeness and accuracy of their reports. They should adhere to accepted 
guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or 
otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should 
be declared in the publication. Reports of research not in accordance with the principles of this Declaration 
should not be accepted for publication. 
 
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE 
 
31. The physician may combine medical research with medical care only to the extent that the research is 
justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to 
believe that participation in the research study will not adversely affect the health of the patients who serve 
as research subjects. 
 
32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the 
best current proven intervention, except in the following circumstances:  
• The use of placebo, or no treatment, is acceptable in studies where no current proven intervention 
exists; or 
• Where for compelling and scientifically sound methodological reasons the use of placebo is 
necessary to determine the efficacy or safety of an intervention and the patients who receive placebo 
or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be 
taken to avoid abuse of this option. 
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33. At the conclusion of the study, patients entered into the study are entitled to be informed about the 
outcome of the study and to share any benefits that result from it, for example, access to interventions 
identified as beneficial in the study or to other appropriate care or benefits. 
 
34. The physician must fully inform the patient which aspects of the care are related to the research. The 
refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never 
interfere with the patient-physician relationship 
. 
35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the 
physician, after seeking expert advice, with informed consent from the patient or a legally authorized 
representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, 
re-establishing health or alleviating suffering. Where possible, this intervention should be made the object of 
research, designed to evaluate its safety and efficacy. In all cases, new information should be recorded and, 
where appropriate, made publicly available. 
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INVESTIGATOR PROTOCOL APPROVAL FORM 
 
Protocol title: A Phase IV, randomised study to evaluate the immune responses of UK adolescent 
girls receiving CervarixTM or GardasilTM Human Papillomavirus vaccines (study code HPV CSP01) 
 
 
I have read and approved the attached protocol. I shall comply with its contents and I 
accept the investigator responsibilities as defined in the 1996 ICH GCP guidelines. 
 
 
 
___________________________  _    _/_     _/____ 
Investigator Signature     Date 
 
 
 
____________________________ __________________________ 
Investigator Name    Title 
 
Address 
______________________________________________________ 
______________________________________________________ 
______________________________________________________ 
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GENERAL PRACTITIONER PROTOCOL APPROVAL FORM 
 
Protocol title: A Phase IV, randomised study to evaluate the immune responses of UK adolescent 
girls receiving CervarixTM or GardasilTM Human Papillomavirus vaccines (study code HPV CSP01) 
 
The attached protocol has been read and approved according to our practice procedure. I 
confirm, on behalf of the GPs at the Surgery named below, that this study has been 
approved to take place in the Surgery such that patients may be approached to participate 
by Health Protection Agency Vaccine Research Nurse.   
 
The Surgery will be provided with a site file (see index pages in Appendix 4). Included 
there is a list of responsibilities. The GPs at the Surgery are willing to comply with these, 
such that we:  
• Ensure appropriate management of patients involved in the study according to practice 
protocol for vaccination 
• Undertake to report, where possible, all serious / severe adverse events to the 
investigators or Vaccine Research Nurses (VRNs) as quickly as possible so that 
appropriate action can be taken 
• Allow VRNs to vaccinate at surgery and have access to patient records 
 
 
___________________________          __/_       _/____ 
Signature of Surgery representative  Date 
 
 
____________________________ __________________________ 
Name      Title 
 
 
Surgery address/ stamp 
 
______________________________________________________ 
 
______________________________________________________ 
 
